Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies

T cell-based immunotherapy, for example, with T cell-recruiting bispecific antibody (bsAb), has revolutionized oncological treatment. However, many patients do not respond to treatment, and long-term remissions are still rare. Several tumor immune evasion mechanisms have been reported to counteract...

Descripción completa

Detalles Bibliográficos
Autores principales: Lutz, Martina Svenja, Klimovich, Boris, Maurer, Stefanie, Heitmann, Jonas S, Märklin, Melanie, Zekri, Latifa, Jung, Gundram, Salih, Helmut R, Hinterleitner, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811601/
https://www.ncbi.nlm.nih.gov/pubmed/35110356
http://dx.doi.org/10.1136/jitc-2021-003655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811601/
https://www.ncbi.nlm.nih.gov/pubmed/35110356
http://dx.doi.org/10.1136/jitc-2021-003655

Ejemplares similares